Atopix Therapeutics Appoints CMO
This article was originally published in Scrip
Atopix Therapeutics Limited, a UK-based biotechnology company developing medicines to treat atopic dermatitis and severe asthma, has appointed Dr Andrew Zambanini chief medical officer. Zambanini has 25 years of experience in clinical medicine and the pharmaceutical industry. He has previously held positions at GlaxoSmithKline plc, where from 2003 until 2010 he held a variety of roles of increasing seniority up to vice-president level; Takeda Global R&D; Novartis AG; Kyowa Hakko Kirin UK; ProStrakan; Gilead Sciences; and Circassia.